The company also announced it has initiated AGLOW, a Phase 2 proof-of-concept study of VX-407 for the treatment of ADPKD. VX-407 is an investigational small molecule corrector that is designed to ...
Vertex Pharma has made its name with treatment for cystic fibrosis, but has big plans in cell and genetic therapies – and has just chalked up fast-track status from the FDA for a cell-based therapy ...
You can create a release to package software, along with release notes and links to binary files, for other people to use. Learn more about releases in our docs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback